Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernd Wullich

Showing results (181-190 of 251) with videos related to

Pageof 26
Sort By:
Oncotarget|January 19, 2017
A new semisynthetic cardenolide analog 3β-[2-(1-amantadine)- 1-on-ethylamine]-digitoxigenin (AMANTADIG) affects G2/M cell cycle arrest and miRNA expression profiles and enhances proapoptotic survivin-2B expression in renal cell carcinoma cell linesElke Nolte, Sven Wach, Izabella Thais Silva, et al.
Molecular Cancer|February 7, 2007
Factor interaction analysis for chromosome 8 and DNA methylation alterations highlights innate immune response suppression and cytoskeletal changes in prostate cancerWolfgang A Schulz, Adrian Alexa, Volker Jung, et al.
Frontiers in Oncology|May 10, 2021
Endogenous Retroviral-K Envelope Is a Novel Tumor Antigen and Prognostic Indicator of Renal Cell CarcinomaVeronika Weyerer, Pamela L Strissel, Christine Stöhr, et al.
The Journal of Biological Chemistry|November 7, 2019
Hypoxia drives glucose transporter 3 expression through hypoxia-inducible transcription factor (HIF)-mediated induction of the long noncoding RNA NICIVictoria Lauer, Steffen Grampp, James Platt, et al.
Frontiers in Immunology|October 29, 2024
HLA-G expression associates with immune evasion muscle-invasive urothelial cancer and drives prognostic relevanceAnnalena Branz, Christian Matek, Fabienne Lange, et al.
Urologia Internationalis|November 6, 2023
Patient Benefits of Radical Prostatectomy in Certified Prostate Cancer Centers: Comparative Results from the Multicenter IMPROVE StudyDanijel Sikic, Christian Fiebig, Bernd Wullich, et al.
The Prostate|November 7, 2017
<sup>99m</sup> Tc-MIP-1404-SPECT/CT for the detection of PSMA-positive lesions in 225 patients with biochemical recurrence of prostate cancerChristian Schmidkonz, Claudia Hollweg, Michael Beck, et al.
Clinical Pharmacology and Therapeutics|December 22, 2025
Extent and Incidence of Pseudo-Worsening of Kidney Function Due to Oral Antitumor Therapeutics in the AMBORA Cohort: An Analysis of Real-World DataMichael I Sponfeldner, Pauline Dürr, Phyllis Lensker, et al.
Urologia Internationalis|December 20, 2016
ERBB2 Expression as Potential Risk-Stratification for Early Cystectomy in Patients with pT1 Bladder Cancer and Concomitant Carcinoma in situJohannes Breyer, Wolfgang Otto, Ralph M Wirtz, et al.
International Journal of Cancer|March 11, 2015
The combined serum levels of miR-375 and urokinase plasminogen activator receptor are suggested as diagnostic and prognostic biomarkers in prostate cancerSven Wach, Omar Al-Janabi, Katrin Weigelt, et al.
Pageof 26

Showing results (181-190 of 251) with videos related to

Sort By:
Pageof 26
Oncotarget|January 19, 2017
A new semisynthetic cardenolide analog 3β-[2-(1-amantadine)- 1-on-ethylamine]-digitoxigenin (AMANTADIG) affects G2/M cell cycle arrest and miRNA expression profiles and enhances proapoptotic survivin-2B expression in renal cell carcinoma cell linesElke Nolte, Sven Wach, Izabella Thais Silva, et al.
Molecular Cancer|February 7, 2007
Factor interaction analysis for chromosome 8 and DNA methylation alterations highlights innate immune response suppression and cytoskeletal changes in prostate cancerWolfgang A Schulz, Adrian Alexa, Volker Jung, et al.
Frontiers in Oncology|May 10, 2021
Endogenous Retroviral-K Envelope Is a Novel Tumor Antigen and Prognostic Indicator of Renal Cell CarcinomaVeronika Weyerer, Pamela L Strissel, Christine Stöhr, et al.
The Journal of Biological Chemistry|November 7, 2019
Hypoxia drives glucose transporter 3 expression through hypoxia-inducible transcription factor (HIF)-mediated induction of the long noncoding RNA NICIVictoria Lauer, Steffen Grampp, James Platt, et al.
Frontiers in Immunology|October 29, 2024
HLA-G expression associates with immune evasion muscle-invasive urothelial cancer and drives prognostic relevanceAnnalena Branz, Christian Matek, Fabienne Lange, et al.
Urologia Internationalis|November 6, 2023
Patient Benefits of Radical Prostatectomy in Certified Prostate Cancer Centers: Comparative Results from the Multicenter IMPROVE StudyDanijel Sikic, Christian Fiebig, Bernd Wullich, et al.
The Prostate|November 7, 2017
<sup>99m</sup> Tc-MIP-1404-SPECT/CT for the detection of PSMA-positive lesions in 225 patients with biochemical recurrence of prostate cancerChristian Schmidkonz, Claudia Hollweg, Michael Beck, et al.
Clinical Pharmacology and Therapeutics|December 22, 2025
Extent and Incidence of Pseudo-Worsening of Kidney Function Due to Oral Antitumor Therapeutics in the AMBORA Cohort: An Analysis of Real-World DataMichael I Sponfeldner, Pauline Dürr, Phyllis Lensker, et al.
Urologia Internationalis|December 20, 2016
ERBB2 Expression as Potential Risk-Stratification for Early Cystectomy in Patients with pT1 Bladder Cancer and Concomitant Carcinoma in situJohannes Breyer, Wolfgang Otto, Ralph M Wirtz, et al.
International Journal of Cancer|March 11, 2015
The combined serum levels of miR-375 and urokinase plasminogen activator receptor are suggested as diagnostic and prognostic biomarkers in prostate cancerSven Wach, Omar Al-Janabi, Katrin Weigelt, et al.
Pageof 26